Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. - Wikidata - wikimedia - TriplyDB

Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses.

Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses.

http://www.wikidata.org/entity/Q40284512

about

Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: comparison among well-stirred, parallel-tube, distributed and dispersion models.Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen.Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin Effect of grapefruit juice on clarithromycin pharmacokinetics Oral cimetidine prolongs clarithromycin absorption Clinical trial of clarithromycin for lepromatous leprosy.Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments Pharmacokinetic interaction between ritonavir and clarithromycin.Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin.Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects.High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I.In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.Interaction between midazolam and clarithromycin in the elderly Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers.Long-term and per rectum disposition of Clarithromycin in the desert tortoise (Gopherus agassizii).Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration Pharmacokinetics of EDP-420 after multiple oral doses in healthy adult volunteers and in a bioequivalence study.Interethnic differences in pharmacokinetics of antibacterials.Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid.Delirium probably induced by clarithromycin in a patient receiving fluoxetine.Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers.

P2860

Q31007816-E9F38EDB-CC04-47FA-8B5D-EFB958EE70B3 Q33541485-36E88A2A-A5D4-480E-9AA9-F03625667909 Q33613354-B15162AF-EC2E-41BF-B885-EEA365851774 Q33692862-3FCF9C13-4213-4831-8410-07DB09CA15C3 Q33693909-12C3B4CC-1666-421D-BFFE-ECFE492F65B6 Q33750992-B5198D78-99EF-43E8-83B8-D2C448C9BE19 Q33763177-A026A8C9-E0E0-44CF-9852-19DB8A0D9406 Q34754557-A2CDEBF7-4367-4DE6-8892-E2EA879B20D3 Q35111440-6CF8855A-127D-4081-A74A-E6CA2A1B25D1 Q35125517-0997A8B1-DDAF-496F-A6E4-448688969F82 Q35818575-603C562F-EBF7-4929-9F18-E3FA3815B0EA Q35904249-9B9F598E-C799-4E37-8372-53B3C6369617 Q36056408-69DDB29B-DA98-4938-8B8E-7472561596A7 Q36072448-4836CC9E-E63E-4188-8D67-764594DA3044 Q36536037-4FD776B7-D5B4-486F-800E-6755E455D6D7 Q37036473-05639C5D-7095-4566-9A19-3C9CEF551CC9 Q37190854-2CE67E73-F99A-4B72-AC46-3251AB1D6091 Q37223359-C24D488E-1B86-4B48-A44D-2CC35054C30A Q37247655-CCE6E5E9-618E-4A6F-94E9-9415F5E7DEA7 Q37274742-630D42B6-42CD-4439-B6C5-304EDEB2EFC0 Q38266806-66120507-F00D-4E56-A921-4B0AC9EB6CBB Q38287050-2D559020-0FB9-4CA3-BD52-A96D4B167DDC Q39866698-D4EE14F1-FF5A-45CD-9F21-1A2E9094BE6E Q42277601-A1D3ADE3-7FFC-4340-8E4E-A9FD0863B6AE Q54010969-4A5E1915-5D07-4717-942C-BF9FCDDE5890

P2860

Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses.

http://www.wikidata.org/entity/Q40284512

description

1992 nî lūn-bûn

@nan

1992年の論文

@ja

1992年論文

@yue

1992年論文

@zh-hant

1992年論文

@zh-hk

1992年論文

@zh-mo

1992年論文

@zh-tw

1992年论文

@wuu

1992年论文

@zh

1992年论文

@zh-cn

name

Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses.

@en

type

label

Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses.

@en

prefLabel

Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses.

@en

P1433

Q40284512-EA4EEDBD-4CAA-49A4-A89F-90494D402019

P1476

Q40284512-C70698B5-42D7-4410-A437-0FEDC52340E0

P2093

Q40284512-05B3EC23-8113-443D-89F7-AF8103ECFF39

Q40284512-0E1139F5-9EE5-4C02-AAE5-BEA7203116AB

Q40284512-A9C3E770-DB09-4FB9-AFC0-FBF8E18D94F5

Q40284512-C3DDFDCE-7325-4F61-8D1F-414559B7EAB9

Q40284512-C8655434-7B13-4B05-B8C0-ACB1C9D15570

Q40284512-F2EBD2DA-A4AD-4F2F-9ECF-11DEE249D12E

P2860

Q40284512-0A4E7F06-5E5F-419F-9FCD-DE3E29D28DD5

Q40284512-23A0FA97-02E4-4D21-836D-8D447E3722EA

Q40284512-24915202-FF64-4ADA-8AB1-9013E1619733

Q40284512-36067324-6DF4-44AA-87E9-5E521EB76E8F

Q40284512-5D785705-7314-4BB5-8A2D-F81AD8294DC8

Q40284512-6311E34E-46FC-4D1E-B532-7AEC35B31A20

Q40284512-715F2261-5ADC-4394-97CB-4AD3DD217228

Q40284512-BBB26CC9-B830-4226-B5F2-8EEDC51A06CC

Q40284512-C2554C91-54B9-47B4-ABD0-F10F9300ABCE

Q40284512-C8FE85B1-A417-415E-AEB9-B23F4A17A5D0

P304

Q40284512-74F5524F-5D31-44BB-85FE-3FDA9AB55C28

P31

Q40284512-F0FC6B55-F424-4C32-A08A-A5C2EBACDA21

P356

Q40284512-1B5D3281-53DE-406B-999D-D351A32D6CEA

P407

Q40284512-DC47376E-F5D0-489C-957E-70EB9CA4ED61

P433

Q40284512-14563792-9B03-4B0D-84C2-4C3E5C3CE5F4

P478

Q40284512-AEC22317-9B51-46C0-B085-0E13584CFC99

P577

Q40284512-64C7F83A-3931-4E0C-9554-C3D9C78D479D

P698

Q40284512-06DD966B-86AB-43A9-8A3F-38BF25C93929

P932

Q40284512-10092184-0845-47D5-8B94-E0D746F208C1

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses.

@en

P2093

Bunnell ST

http://www.w3.org/2001/XMLSchema#string

Chu SY

http://www.w3.org/2001/XMLSchema#string

Sennello LT

http://www.w3.org/2001/XMLSchema#string

Sonders RC

http://www.w3.org/2001/XMLSchema#string

Varga LL

http://www.w3.org/2001/XMLSchema#string

Wilson DS

http://www.w3.org/2001/XMLSchema#string

P2860

Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages

Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin

Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.

In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide

CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Autobacteriographic studies of clarithromycin and erythromycin in mice.

Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats.

Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base.

In vitro activity of tosufloxacin (A-60969) and clarithromycin (A-56268, TE-031) against resistant Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis isolates.

P304

2447-2453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.36.11.2447

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

1992-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1489187

http://www.w3.org/2001/XMLSchema#string

P932

284351

http://www.w3.org/2001/XMLSchema#string